Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Top Cited Papers
Open Access
- 30 April 2021
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in Morbidity and Mortality Weekly Report (MMWR)
- Vol. 70 (17), 651-656
- https://doi.org/10.15585/mmwr.mm7017e4
Abstract
The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA’s Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18–49 years.Keywords
This publication has 6 references indexed in Scilit:
- Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 VaccinationThe New England Journal of Medicine, 2021
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- Heparin-induced thrombocytopeniaBlood, 2017
- Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2015